Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Drug repurposing

Beta blockers may prolong survival in ovarian cancer patients

Ovarian cancer patients who take non-selective beta blockers live longer than those who take other beta blockers or none at all, study suggests.

Taking a certain type of beta blocker could prolong the lives of women with ovarian cancer by up to five years. In the image, micrograph of ovarian cancer

Source: Nephron / Wikimedia Commons

Women with ovarian cancer who take beta blockers survive longer than women not taking these drugs

Taking a certain type of beta blocker could prolong the lives of women with ovarian cancer by up to five years, a study published in Cancer[1] on 24 August 2015 suggests.

Sustained adrenergic activation has been shown to promote ovarian cancer growth and metastasis in preclinical studies, so researchers from the University of Texas examined the impact of beta-adrenergic blockade on the clinical outcome of women with epithelial ovarian cancer.

The researchers analysed the medical records of 1,425 women who had been treated for epithelial ovarian cancer and found that 269 had been taking beta blockers, usually prescribed for hypertension, arrhythmia or post-myocardial infarction management, at the same time as receiving chemotherapy.

For patients who took any beta blocker, the median overall survival was 47.8 months compared with 42 months for non-users (P=0.04). However, when researchers looked at the type of beta blocker taken, they found significant differences; median overall survival for women for who took non-selective beta blockers was 94.9 months, compared with 38.0 months for those who took beta-1–adrenergic receptor selective agents (P<0.001).

Hypertension was associated with decreased overall survival, but even patients with hypertension appeared to live longer if they took a non-selective beta blocker — median overall survival was 90.0 months compared with 34.2 months for non-users of beta blockers.

Simon Newman, director of research for charity Target Ovarian Cancer, says previous studies have linked high levels of stress with a decrease in survival rates in cancer patients, which supports the findings of the paper.

“This large retrospective clinical study may be the first to clearly show how blocking aspects of the stress response can see an increase in survival for ovarian cancer,” he says. “There are limitations to this study, however, and more trials will need to be done before there is a definitive link. But this exciting study shows how we can learn more about ovarian cancer from existing drugs used for other illnesses, and we may be able to open up new treatment options for ovarian cancer.”

In an accompanying editorial[2], Kristen Bunch, from the Walter Reed National Military Medical Center, and Christina Annunziata, from the National Cancer Institute in the United States, say that the study “lays the groundwork for insightful investigation into repurposing cardiovascular medications to cancer therapeutics”. However, they add that beta blockers can cause significant side effects, which could prevent their widespread use in patients with cancer.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069219

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £81.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Community Pharmacy Handbook

    Community Pharmacy Handbook

    Community Pharmacy Handbook is a survival guide for community pharmacists and students, answering your practical questions. Includes case studies.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Taking a certain type of beta blocker could prolong the lives of women with ovarian cancer by up to five years. In the image, micrograph of ovarian cancer

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.